Specialty
Specialty spend continues to grow rapidly; CVS Health continues to innovate with strategies that reduced the trend impact of inflation significantly, to 1.7 percent. More
Video
“Pipeline”
19 result(s)
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q1-Q2 2019 More
Specialty Report
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q3-Q4 2018 More
Specialty Report
Drug Pipeline
When the FDA approves a “supplemental indication” for a drug already on the market — permitting it to be used for new conditions or stages of a disease, or additional patient... More
Briefing
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q2-Q3 2018 More
Specialty Report
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q1-Q2 2018 More
Specialty Report
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q4 2017-Q1 2018 More
Specialty Report
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q3-Q4 2017 More
Specialty Report
Specialty
Blockbuster cancer drug Zytiga may become first-line treatment for patients with metastatic, castration-resistant cancer, greatly expanding its market and cost impact. More
Feature
Specialty
Multiple Sclerosis is a $19 billion market worldwide, and the third most expensive specialty drug spend category. Recently approved Ocrevus is likely to add to cost of treatment... More
Briefing